Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

Background Blinatumomab is a BiTE(®) immuno‐oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). AIMS: To assess the efficacy and safety of blinatumomab as first salvage versus second or later salvage in...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Med
Hoofdauteurs: Topp, Max S., Stein, Anthony S., Gökbuget, Nicola, Horst, Heinz‐August, Boissel, Nicolas, Martinelli, Giovanni, Kantarjian, Hagop, Brüggemann, Monika, Chen, Yuqi, Zugmaier, Gerhard
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2021
Onderwerpen:
Clinical Cancer Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8026950/
https://ncbi.nlm.nih.gov/pubmed/33734596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3731
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items